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ABSTRACT
SYNTHESIS OF COMPOSITES FROM CELLULOSE, CHITOSAN, AND
CIPROFLOXACIN HCl ENCAPSULATED IN
SPOROPOLLENIN CAPSULES

Mark Mitmoen
Marquette University, 2021

In order to be effective dressings for the treatment of infected wounds in the battlefield, it
is essential that composite materials made from the biopolymers Cellulose and Chitosan contain
broad-spectrum antibiotic drugs. These drugs must first be encapsulated into microcapsules in
order to protect them from the manufacturing process, ensuring that they remain in a usable form
in the final product. Here we demonstrate the successful encapsulation of Ciprofloxacin HCl into
Sporopollenin Exine Capsules (SEC) to produce Cipro@SEC, followed by incorporation of
Cipro@SEC into a polymer composite consisting of a mixture of Cellulose and Chitosan
dissolved in 1-butylmethylimidazolium chloride, an ionic liquid solvent. We also overcome the
challenge that arises from Ciprofloxacin HCl’s solubility in water by developing the use of 2propanol in the place of water for the gelification of the composites and the removal of the ionic
liquid solvent.
Ciprofloxacin HCl solution and SEC were mixed together under a high vacuum in order
to encapsulate dry Ciprofloxacin HCl into the inner cavity of the SEC, producing Cipro@SEC.
Five sequential encapsulations were carried out to ensure complete filling of the SEC. Cellulose
and Chitosan were dissolved in 1-butylmethylimidazolium chloride under vigorous stirring at 120
°C to produce a polymer composite ([CEL+CS]). Cipro@SEC was added to the polymer
composite at 90 °C to produce [CEL+CS+Cipro@SEC]. [CEL+CS+Cipro@SEC] composites
were cast into Teflon molds on Mylar film and allowed to gelify in a desiccated 2-propanol
atmosphere. After washing with 2-propanol to remove the 1-butylmethylimidazolium chloride,
the composites were dried at high vacuum.
The produced Cipro@SEC were characterized with confocal fluorescence microscopy,
analysis of SEM images, fluorescence spectra, XRD spectra, and FTIR spectra. The produced
[CEL+CS+Cipro@SEC] composites were characterized with analysis of SEM images,
fluorescence spectra, XRD spectra, FTIR spectra, and visual analysis. The Cipro@SEC were
found to be completely filled with Ciprofloxacin HCl and were observed to be covered with
crystallized Ciprofloxacin HCl from the encapsulation process. The dried
[CEL+CS+Cipro@SEC] composite was found to contain three different species of Ciprofloxacin:
Ciprofloxacin Hydrochloride, Ciprofloxacin, and an anhydrous form of Ciprofloxacin
Hydrochloride.
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Chapter 1. INTRODUCTION

1.1. Background
The use of synthetic polymers has been very beneficial to society, producing a variety of
products that have improved the quality of life for many people.1 However, synthetic polymers
are typically manufactured from petroleum products and as such are inherently nonrenewable.2
Furthermore, synthetic polymers often cannot be easily broken down by nature.2 They accumulate
in the environment and in landfills, and can persist for centuries.2 Polymers that are derived from
natural sources instead of petroleum based sources are currently being investigated in order to one
day replace synthetic polymers.3 Natural polymers have several useful properties or qualities that
increase their attractiveness over synthetic polymers. These include, but are not limited to:
biodegradability, biocompatibility, nontoxicity, relative cheapness, natural abundance, and
renewability.3 This study was initiated in an effort to utilize the attractive qualities of biopolymers
toward the development of a novel synthetic procedure to produce polysaccharide composite
materials. Cellulose (CEL), the most abundant biopolymer on earth, was chosen in part as the
focus of this study.4 Cellulose has exceptional mechanical and rheological properties which will
be used to strengthen the resulting multi-component composite materials.4 The other biopolymer
that was used in this study was Chitosan (CS). Chitosan’s properties and abilities, such as
antibacterial action5, mucoadhesivity6, hemostativity7, and wound healing promotion8, allow
composite materials that incorporate Chitosan to be used for a variety of medical applications. In
order to strengthen the natural antibiotic action of Chitosan for applications in which the polymer
composite would be used for treating infected wounds, the broad-spectrum antibiotic
Ciprofloxacin9 was also incorporated into the composite material.
A primary challenge when working with Cellulose and Chitosan is that they are not well
soluble in common organic solvents or solvent systems under reasonably mild conditions.4,10
Fortunately, the discovery of Ionic Liquids has provided an alternative. One such Ionic Liquid, 1-

2
butyl-3-methylimidazolium chloride ([BMIM+Cl-]), has been shown to be able to dissolve both
Cellulose2 and Chitosan12 and can even keep both biopolymers in the same solution
simultaneously, enabling the production of [CEL+CS] composite materials13-15.
Unfortunately, the synthetic procedure required to produce, gelify, wash, and dry
[CEL+CS] composites is also likely to wash the Ciprofloxacin out of the final polymer composite
if it were to be directly added to the polymers dissolved in [BMIM+Cl-]. Because of this,
Ciprofloxacin will be encapsulated into durable, biodegradable, biocompatible, nontoxic, and
nonallergenic capsules derived from Lycopodium Clavatum pollen grains, known as
Sporopollenin Exine Capsules (SEC)16-18. Sporopollenin Exine Capsules are produced in a simple
synthetic process that involves refluxing the raw pollen in acetone, followed by sequential reflux
in phosphoric acid and potassium hydroxide to produce clean, empty SEC.19 The production
procedure for SEC will be described in detail in a subsequent section. Encapsulation of
Ciprofloxacin into SEC in the form of Ciprofloxacin HCl (a more water-soluble form of
Ciprofloxacin20,21) to produce Cipro@SEC will protect the Ciprofloxacin HCl from the
incompatible conditions of the synthetic produce, allowing the antibiotic to remain in a useable
form in the final [CEL+CS+Cipro@SEC] composite.22
A significant modification that was made to the synthetic procedure as previously
reported13-15 is the use of an alternative gelification and washing solvent, 2-propanol.20,21 This
decision was made in order to prevent the water-soluble Ciprofloxacin HCl from being washed
away during the synthetic procedure.20,21 The use of 2-propanol in the modified synthetic
procedure will be described in detail in Chapter 3. A brief description of some selected properties
of Cellulose, Chitosan, Ionic Liquids, Sporopollenin Exine Capsules, and Ciprofloxacin will be
given in the following sections as an introduction to the material.
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1.2. Cellulose
Cellulose is the most abundant biopolymer on Earth, with 1.5x1012 tons of it being
produced by nature each year.4 It is a polysaccharide composed of polydisperse glucose chains of
varying lengths, with the length of each chain varying anywhere between 300 units to 10000
units, depending on the source of the cellulose.4 Each glucose unit is bound to the next unit
through a (β-1,4-glucan) covalent bond.4 The structure of the cellulose polymer has been
displayed in Figure 1.1.
Figure 1.1: Structure of a Single Chain of Cellulose.11

Cellulose polymers form a vast hydrogen bond network with each other, providing the
bulk material with stiffness and durability. An illustration of the intermolecular and
intramolecular hydrogen bonds is provided in Figure 1.2. Being a natural product, cellulose is
biocompatible and can be used in medical applications such as the one that is the ultimate goal of
this study. While there are several solvent systems that can dissolve Cellulose, utilizing ionic
liquids is the only method that can be considered “green”.4
Some ionic liquids are hygroscopic.23 The presence of water in the ionic liquid is known
to greatly decrease the effectiveness of the solvent.11 In fact, only 1% by weight in water is
enough to change Cellulose from being soluble in the ionic liquid, to being insoluble.11 Because
of this, it is important to keep the ionic liquid as dry as possible while dissolving biopolymers.
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Figure 1.2: Top-Down View of the Intermolecular and Intramolecular Hydrogen Bonds
Present in a Single Sheet of Cellulose.24

1.3. Chitosan
Chitosan is a polysaccharide polymer derived from chitin. Since chitin is the second most
abundant naturally occurring biopolymer after cellulose, chitosan can also be considered a
renewable resource.10 It is also known as deacetylated chitin since it is produced by deacetylating
the chitin with sodium hydroxide. This deacetylation is not carried to completion, however, and
so in a single polymer strand there will be a random distribution of β-(1-4)-linked D-glucosamine
and N-acetyl-D-glucosamine monomers.10 A schematic showing the structural differences
between chitin and chitosan has been provided in Figure 1.3.
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Figure 1.3: Structural Comparison of Chitin and Chitosan25

In an acidic environment, chitosan polymer chains will have a positive charge due to the
protonation of the amine groups along its length.10 Being derived from a natural biopolymer,
chitosan is simultaneously biocompatible, biodegradable, and nontoxic.26 Materials made from
chitosan also show the ability to assist in clotting open wounds.7,8 In fact, such materials have
been approved by the US military for use as hemostatic agents to quickly stop arterial bleeds.10
When applied to an open wound, chitosan’s positive charge attracts the negatively charged red
blood cells along with the platelets, greatly increasing the speed of clot formation.10
Chitosan is antimicrobial and can be used in wound dressings, as has been confirmed
previously by our research group.27 While composites made purely from chitosan have
insufficient mechanical properties, a hybrid composite can be made by dissolving cellulose and
chitosan together in ionic liquid.13-15,27 Such a composite has the high mechanical strength of
cellulose, while retaining all of the attractive properties of chitosan that are required for use in
biomedical applications.13,27
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While hybrid composites made from cellulose and chitosan polymers dissolved in ionic
liquid will retain the antimicrobial properties of chitosan, this natural anti-microbial action will be
insufficient if such composites are used on an infected wound in a hostile environment, such as a
battlefield. Because of this, it is necessary to incorporate a suitable antibiotic into such a hybrid
polymer composite.
1.4. Ionic Liquids
Ionic liquids are materials that consist of cations and anions, yet still remain a liquid at or
below 100 °C. In other words, ionic liquids are salts that can be molten at reasonably low
temperatures. Some commonly used cations and anions have been displayed in Figure 1.4.23
Figure 1.4: Common Cations and Anions Used in Ionic Liquids.23

Ionic liquids have innumerable uses, only some of which are shown in Figure 1.5. To
some extent, the properties of an ionic liquid solvent are “tunable”: the cation and the anion can
each be modified or exchanged, leading to millions of possible systems of cations and anions.23
These different systems can be used to tune solubilities of compounds in the ionic liquid, or even
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change the kinetics or products of certain reactions.23 Perhaps most significantly, ionic liquids
have negligible vapor pressures.23 This non-volatility makes their use as a laboratory solvent
attractive.
Figure 1.5: Applications of Ionic Liquids23

In the present study, the simple ionic liquid “1-butylmethylimidazolium chloride”
([BMIM+Cl-]) was used as the sole solvent in the dissolution of cellulose and chitosan polymers.
This solvent can be collected and purified for later reuse if desired.23
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1.5. Ciprofloxacin
The antibiotic used in this research was ciprofloxacin, a potent fluoroquinolone with
broad-spectrum antibiotic action.9 This antibiotic is widely used and can target both Grampositive and Gram-negative bacteria.9 It is typically used as an antibiotic of “last resort”.9 When
tested against Gram-negative bacteria, the minimum inhibitory concentration of ciprofloxacin is
superior to that of the other fluoroquinolones.9
The antibiotic action of ciprofloxacin comes from the binding of ciprofloxacin to the
bacterial topoisomerases II (DNA gyrase) and IV.28 These enzymes are required for proper DNA
replication and chromosomal separation during mitosis, and the inhibition of these enzymes leads
to the death of the bacterium.28 Unfortunately, ciprofloxacin is only slightly soluble in water, at
0.06 mg/mL.20 In order to work with higher concentrations of ciprofloxacin, the more soluble
hydrochloride form must be used, yielding a solution with a concentration of about 30 mg/mL at
room temperature.21 The structure of ciprofloxacin HCl is shown in Figure 1.6.
Figure 1.6: Structure of Ciprofloxacin Hydrochloride.29

To make ciprofloxacin HCl from neutral ciprofloxacin, it must simply be dissolved in
aqueous HCl to a pH of less than 3.29 At this pH, the ciprofloxacin is in the form shown in Figure
1.6. For reference, a diagram displaying all pKa values for ciprofloxacin is shown in Figure 1.7.
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Figure 1.7: pKa Values of Ciprofloxacin.30

1.6. Sporopollenin Exine Capsules
In order to ensure that any ciprofloxacin HCl that is added to the hybrid polymer
composite survives the manufacturing process and remains in a usable form, it should be
contained within a highly durable microcapsule. While ciprofloxacin HCl has been encapsulated
into synthetic polymer microcapsules before, it has not been encapsulated into an inherently
biocompatible microcapsule for use in medical applications.
The outer shell (exine) of plant and mold pollen is made up of a heavily cross-linked
biopolymer known as sporopollenin. Sporopollenin is a very durable material. When pollen
grains are processed with a series of harsh solvents19, intact empty exine shells can be obtained.
When considering pollen from any particular species of plant or mold, the pollen grains are
remarkably monodisperse. These Sporopollenin Exine Capsules (SEC) can then be filled with
either polar or nonpolar material by application of a vacuum. Material gains access to the inner
cavity of the pollen through numerous nanoscale channels.31
Sporopollenin consists of C, H, and O atoms, but because of its incredible chemical
stability, a full understanding of the chemical structure of the sporopollenin polymer remains
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elusive.31 It is known that the surface of the polymer has phenolic, alkane, alkene, ketone, lactone,
and carboxylic acid groups, but their precise arrangement is not yet understood.31
The development of a method to encapsulate ciprofloxacin inside the cavity of
sporopollenin exine capsules will be described in Chapter 2. The characterization of the resulting
Cipro@SEC will also be described, via the methods of FTIR, XRD, Fluorescence, Confocal
Fluorescence Microscopy, and SEM analysis. In Chapter 3, the incorporation of Cipro@SEC into
biopolymer composite materials using cellulose, chitosan, and [BMIM+Cl-] ionic liquid as the
sole solvent will be described. The resulting novel composites will be characterized using such
methods as FTIR, XRD, Fluorescence, and SEM analysis. In Chapter 4, overall conclusions of
the work are presented, followed by a discussion of the future directions of the research described
herein.
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Chapter 2. SYNTHESIS OF ENCAPSULATED CIPROFLOXACIN HCl

2.1. Background
2.1.1. Ciprofloxacin
As described in Chapter 1, ciprofloxacin is a widely used synthetic antibiotic. It is one of
the most potent fluoroquinolones, effective against both Gram-positive and Gram-negative
bacteria.1 The inhibitory action comes from the binding of ciprofloxacin to the bacterial
topoisomerases II (DNA gyrase) and IV.2 These enzymes are critical to the replication of DNA
and subsequent chromosomal separation, and the inhibition of their normal function leads to
bacterial death.2 The structure of ciprofloxacin is shown in Figure 2.1.

Figure 2.1: Chemical Structure of Ciprofloxacin.
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2.1.2. Encapsulation
To protect the ciprofloxacin and ensure its stability, the ciprofloxacin must be
encapsulated. Encapsulation isolates the ciprofloxacin inside a capsule, protecting it from any
harsh external chemical environments.3 This allows the ciprofloxacin to be used for applications
in which the chemical properties of ciprofloxacin would otherwise be incompatible.3 The ideal
capsule for encapsulation of ciprofloxacin would be mechanically robust, chemically resistant to
acidic and alkaline environments, thermally stable, biocompatible, and biodegradable.
Sporopollenin exine capsules have been shown to possess all of these properties, as well as
having the additional benefits of monodispersity and being naturally abundant biomaterials.4
2.1.3. Sporopollenin Exine Capsules from Natural Pollen Grains
Pollen is the male component of flowering plant reproduction.4 It is produced in mass
quantities in the anther, and spreads to the female component of the flower either by wind
dispersal or by direct transfer from insects.4 Pollen grains contain the genetic material inside a
durable, double-walled capsule.4 The inner layer is called the intine and is made of cellulose.4 The
outer layer is made of sporopollenin, an extremely durable biopolymer. In fact, it is so durable
that its complete structure has not yet been determined.4 It is known that the polymer has
phenolic, alkane, alkene, ketone, lactone, and carboxylic acid groups, but their precise
arrangement is not yet understood.5,6
Sporopollenin exine capsules can be obtained from processing natural pollen grains with
a sequence of solvents and chemical reagents. The specifics of the processing procedure will be
explained in detail in a later section. This process removes the cellulose intine, the inner genetic
material, and any proteins. Protein removal can be verified by combustion elemental analysis,
which has been shown to demonstrate that the resulting empty exine capsules are composed
entirely of carbon, hydrogen, and oxygen.4,7
The sporopollenin exine capsules (SEC) used in this study were obtained from
Lycopodium clavatum pollen, also known as running clubmoss.8 This species of plant is known to
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produce one of the most robust pollens, with the typical pollen grain having a diameter of 25 μm.4
In general, SEC are physically durable, able to resist both acidic and basic conditions, thermally
stable, biodegradable, biocompatible, nontoxic, and nonallergenic.4,9,10 Lycopodium clavatum
SEC are slightly porous due to the presence of nanoscale channels that span the wall of the
capsule.4 This slight porosity can be utilized to fill the inner cavity with a liquid solution.4 While
simply placing the SEC into a liquid solution will cause the inner cavity to be slowly filled, the
application of a vacuum greatly speeds up the process.4 Another advantage of using vacuum
encapsulation is that an aqueous solution can then be dried inside the capsule by the vacuum,
filling the inner cavity with solid material.
In this work, the vacuum encapsulation method will be used to completely fill the inner
cavity of SEC from Lycopodium clavatum with an aqueous solution of ciprofloxacin, which is
then dried inside the cavity by continued application of the vacuum. Ciprofloxacin is weakly
soluble in water in its neutral form, at about 0.06 mg/mL.11 However, its protonated form has a
solubility of about 30 mg/mL.12 In order to work with this antibiotic at higher concentrations and
therefore increase the efficiency of the process, the protonated form of ciprofloxacin was
prepared from the neutral form.
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2.2. Materials and Methods
2.2.1. Chemicals
Hydrochloric acid (37%) was purchased from Macron Fine Chemicals. Ciprofloxacin
was purchased from TCI America and acidified to synthesize ciprofloxacin HCl.13,14 Lycopodium
clavatum pollen powder was purchased from PFaltz & Bauer and cleaned to produce
Sporopollenin Exine Capsules (SEC) as described previously.7,15,16 Acetone, orthophosphoric acid
(85%), ethanol (190 proof), and potassium hydroxide (87.7%) were purchased from Fisher
Scientific Company and used to process the pollen. Sodium hydroxide (98%) was purchased from
Acros Organics and used to process the pollen. 1-octanol was purchased from Sigma-Aldrich and
used to affix pollen samples for confocal fluorescence analysis.
2.2.2. Instruments
FTIR spectra were collected on a PerkinElmer Spectrum 100 FT-IR Spectrometer using
the ATR method. The MIRacle ATR from PIKE Technologies accessory was used with a ZnSe
crystal. Spectra were recorded from 650-4000 cm-1 with a resolution of 4 cm-1 and an average of
100 scans.
X-ray powder diffraction (XRD) spectra were collected on a Rigaku MiniFlex II
diffractometer using Ni filtered Cu Kα radiation (1.54059Å). The X-ray tube had a voltage of 30
kV and a current of 15 mA. The samples were measured from 5.0-50.0° (2θ) at a scan rate of
8°/min and the resulting spectra were an average of 3 scans. Data was processed using the Jade 8
software.
Solid-state fluorescence measurements were collected on a Quanta Master
spectrofluorometer from Photon Technologies International. Samples were held 45° to the
incident beam. Excitation spectra were monitored at 444 nm while the excitation wavelength was
scanned from 230-420 nm at a scan rate of 1 nm/sec. Emission spectra were excited at 279 nm
while the monitoring wavelength was scanned from 350-530 nm at a scan rate of 1 nm/sec. The
slit width was 2 nm.
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Confocal fluorescence images were taken on a Nikon Eclipse Ti-E inverted microscope
with a 60x water objective lens. The microscope utilized the Alexa Fluor 405 (excitation at 405.0
nm, monitored 425-475 nm), FITC (excitation at 488.0 nm, monitored 500-550 nm), and Texas
Red (excitation at 561.0 nm, monitored 570-620 nm) laser lines. The scan speed was 16 fps.
Obtained images were processed and analyzed using the NIS Elements-Microscope Imaging
software from Nikon. Samples were affixed on the slide with 1-octanol.
Scanning electron microscope (SEM) images were collected under vacuum with a JEOL
JSM-6510LV/LGS scanning electron microscope with the standard secondary electron detector
installed. The acceleration voltage was 20 kV. The samples were made conductive via the
application of a 200 nm gold coating with the use of a Technics Hummer VI sputter coater.
2.2.3. Procedure to Synthesize Ciprofloxacin HCl
Hydrochloric acid (37%) was appropriately diluted to produce a 50 mL solution of 0.1 M
hydrochloric acid in a 100 mL beaker. The solution was stirred at 300 rpm while the pH was
monitored with a pH probe. Ciprofloxacin powder was then added in three 500 mg portions and
allowed to completely dissolve between additions to produce a 30 mg/mL ciprofloxacin HCl
solution. A typical batch had a final pH of ~1.93. Solid ciprofloxacin HCl for spectroscopy was
produced by drying 20 mL of the 30 mg/mL ciprofloxacin HCl solution under house vacuum at
room temperature. The resulting solid was then stored in a desiccator.
2.2.4. Procedure to Produce Empty Sporopollenin Exine Capsules
Lycopodium clavatum pollen grains were cleaned to produce empty Sporopollenin Exine
Capsules (SEC) as previously described.7,15,16 The procedure was scaled up appropriately to
accommodate a batch size of 75 g, up from the original 25 g. The pollen (75 g) was refluxed
overnight in acetone (1350 mL, 65 °C) with vigorous stirring. The resulting mixture was vacuum
filtered, and the collected pollen was spread out on a watch glass and allowed to dry overnight.
The dry pollen was then refluxed in 6% w/v orthophosphoric acid (1350 mL, 60 °C) for 7 days.
The solution was then vacuum filtered and washed with hot water (6 x 250 mL), acetone (3 x 250
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mL), 2 M hydrochloric acid (3 x 250 mL), 2 M sodium hydroxide (3 x 250 mL), water (18 x 250
mL), acetone (3 x 250 mL), and ethanol (3 x 250 mL). After the pollen was air-dried overnight, it
was refluxed overnight in 6% w/v potassium hydroxide (1200 mL, 80 °C) with vigorous stirring.
The pollen was then vacuum filtered and washed with hot water (18 x 250 mL), acetone (3 x 250
mL), and hot ethanol (6 x 250 mL). The SEC were then dried at 60 °C until constant weight. The
total yield of this procedure was 21.012 g, or 28.016%. An image of the raw pollen is shown in
Figure 2.2.A, and a photograph of the processed pollen is shown in Figure 2.2.B.
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Figure 2.2: Pollen, Before and After Processing: A) Raw Pollen. B) Processed (SEC).

A

B

2.2.5. Procedure to Encapsulate Ciprofloxacin HCl into SEC
2.2.5.1. First Encapsulation
Sequential encapsulation of ciprofloxacin HCl into SEC was carried out by modifying an
encapsulation procedure from the literature.17 SEC (6.335 g) were placed in a 300 mL roundbottom flask and dried under vacuum at 130 °C for 2 hours to remove any residual internal
moisture. The pollen was then put through a set of sieves to remove any clumps that had formed
and to ensure that the pollen grains were finely divided. The full set of sieves are shown in Figure
2.3 and consists of mesh sizes of 250 μm, 125 μm, 75 μm, 63 μm, and 45 μm. Only the SEC that
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made it through at least the 125 μm sieve after 10 minutes of shaking was used for the
encapsulation (5.049 g). An image of the 125 μm sieve is shown in Figure 2.4 for reference.

Figure 2.3: Sieves. From Top to Bottom, Mesh Sizes are 250 µm, 125 µm, 75 µm, 63 µm, and
45 µm.
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Figure 2.4: 125 μm Sieve.

50 mL of freshly prepared 30 mg/mL ciprofloxacin HCl solution was added to a 300 mL
round-bottom flask equipped with a magnetic stir bar. Under vigorous stirring, 5.049 g of sieved
SEC was slowly added to the solution to make a thin slurry. If the addition of pollen is not
sufficiently slow, clumps may form. The ratio of SEC to liquid was 1 g/10 mL, as prescribed by
the literature.17 Careful observations were made of the slurry’s viscosity as it was swirled by hand
in order to closely replicate it in subsequent encapsulations. A video of the viscosity was also
recorded and reviewed as needed to assist in the preparation of the subsequent encapsulations. A
picture of the encapsulation slurry is shown in Figure 2.5.
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Figure 2.5: Encapsulation Slurry Inside 300 mL Flask, before Installation into Oil Bath.

The flask was installed into a room-temperature oil bath and stirred vigorously with a stir
bar. The flask must not be freely suspended in air, since the evaporation of water during the
encapsulation process would otherwise lower the temperature of the flask until it was very near
the freezing point. Complete evaporation of solutions below room temperature requires a
prohibitive amount of time, even under vacuum, and so a hotplate was used to maintain the
temperature of the oil bath at 20 °C throughout the encapsulation. Without the constant supply of
heat from the hotplate, the evaporative cooling is sufficient to chill the oil bath as well as the
encapsulation flask. As can be seen in Figure 2.6, the spinning stir bar is able to push the slurry
away from the bottom of the flask, forming a small vortex.
A vacuum was slowly applied to the flask to begin the encapsulation. Slow application of
the vacuum is required to minimize splattering from the vigorous boiling that results; the speed of
application is controlled by hand with a valve, shown in Figure 2.7.
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Figure 2.6: Vortex Formation in the Encapsulation Slurry due to Vigorous Stirring, before
Application of Vacuum.
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Figure 2.7: Valve Used to Control Application of Vacuum to Encapsulation Flask.

As the water evaporates, the solution slowly decreases in volume and increases in
viscosity until the resulting thick paste is pushed away from the bottom of the flask by the stir
bar. It then solidifies under the continued application of the vacuum, at which point the stirring is
turned off. This point in the encapsulation is typically reached within 2 hours. The mixture is then
allowed to continue evaporating to dryness for at least 1 additional hour. This is considered the
endpoint of the encapsulation and is shown in Figure 2.8. The vacuum is then released, and the
solid mixture is dislodged from the flask, broken into small chunks, spread out on a watch glass,
and placed in a vacuum desiccator to finish drying overnight.
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Splattering from vigorous boiling of the solution under the reduced pressure from the
vacuum leads to deposition of ciprofloxacin HCl on the walls of the flask, reducing the maximum
yield of the process. This is the source of the whitish material on the inner walls of the
encapsulation flask, as seen in Figure 2.8. The brown material near the bottom of the flask is the
bulk of the product. Ideally, the application of the vacuum is performed slowly enough to
minimize excessive boiling, producing less waste from the splatters. The separation of the two
distinct regions of material for use in subsequent encapsulations is discussed in the next section.

Figure 2.8: End Point of Encapsulation.

If the stir bar is allowed to remain spinning alone in the bottom of the flask instead of
being turned off, the possibility exists for the stir bar to decouple from the stir plate and disrupt
the encapsulation mixture as it is drying, leading to a substantial amount of powder being sucked
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into the liquid nitrogen trap. While the liquid nitrogen trap effectively protects the vacuum pump
from the dust, it is preferable for the dust to remain inside the flask.
2.2.5.2. Processing the Encapsulate
After drying overnight in a desiccator, the encapsulation mixture is further broken up into
a powder with a mortar and pestle. Using only the weight of the pestle is sufficient to break apart
the chunks, especially since excess force may damage the pollen grains. If the encapsulate is not
sufficiently dry, it can be reinserted into the desiccator and vacuumed to dryness.
The resulting encapsulate powder is then shaken on the sieves for 5 minutes. Any clumps
>250 μm are removed, placed in the mortar, very gently broken up as previously described,
followed by another 5 minutes of shaking on the sieves. This process was repeated until the >250
μm chunks were predominantly ciprofloxacin HCl, which is easily differentiated by the lighter
color of the chunks. The >250 μm chunks were then discarded. An image of the >250 μm chunks
and the >125 μm powder is shown in Figure 2.9.
Figure 2.9: Left, >125 μm Powder. Right, >250 μm Chunks. Note the Difference in Color.

It was observed that clumps that were predominantly pollen (more brown) were easily
broken up by this treatment, while clumps that were predominately ciprofloxacin HCl (more
white) remained mostly intact. It was therefore possible to remove the encapsulated pollen from
the majority of the unencapsulated, waste ciprofloxacin HCl.
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The encapsulate that had passed through the 250 μm sieve was then shaken on the
remaining layers of the sieves (125, 75, 63, and 45 μm) for 5 minutes. The encapsulate on the 75
μm sieve, the 63 μm sieve, the 45 μm sieve, and in the “fines” catcher at the bottom was taken
and weighed. The remaining >125 μm encapsulate was shaken on the sieves for an additional 5
minutes, followed by weighing the portion that passed through. This process was repeated until
the portion that passed through after 5 minutes was trivial. The remainder of the >125 μm
encapsulate was then discarded. It is important to note that the >125 μm encapsulate was not
broken up with the mortar and pestle as was the case for the >250 μm encapsulate. The shaking of
the sieves is sufficient to break apart any clumps that are predominantly pollen, leaving behind
any clumps that are predominantly ciprofloxacin HCl.
2.2.5.3. Subsequent Encapsulations
The processed encapsulate (of size < 125 μm) was then placed into a 300 mL roundbottom flask equipped with a magnetic stir bar. Ciprofloxacin HCl solution (30 mg/mL) was then
slowly added by pipette. After each addition, an attempt was made to swirl the mixture. When the
mixture can be swirled, the video that was recorded of the first encapsulation’s viscosity was
reviewed. Small additions of ciprofloxacin HCl solution were made and the solution was swirled
until the apparent viscosity closely approximated the viscosity of the first encapsulation. The
vacuuming steps, drying steps, and processing steps were then carried out as before. This cycle
was repeated until a total of 5 sequential encapsulations had been performed. After each
encapsulation, a small portion of the material was set aside for characterization. A summary of
the process has been provided in Table 2.1. The overall percent yield was 42.6%. The final
product of this process has been shown in Figure 2.10.
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Table 2.1: Summary of Encapsulation Steps.

Weight of Material
Volume of
Ratio Yield Percent
to Encapsulate (mg) Solution (mL) (mL/g) (mg) Yield
1st Encapsulation
5049
50
9.9
6115 93.4%
2nd Encapsulation
6010
40
6.7
5856 81.2%
3rd Encapsulation
5736
28
4.9
5714 86.9%
4th Encapsulation
5599
22
3.9
5276 84.3%
5th Encapsulation
5250
18
3.4
4439 76.7%

Figure 2.10: Final Product of the Encapsulation Process.
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2.3. Results and Discussion
2.3.1. FTIR Analysis
FTIR spectra of ciprofloxacin HCl, SEC, and selected sequential encapsulations of
Cipro@SEC have been presented in Figure 2.11. To guide the eye, vertical dotted lines have been
provided: blue for ciprofloxacin HCl peaks, and green for SEC peaks. The most striking feature
of the ciprofloxacin HCl spectrum, represented by the magenta line, is the twin sharp peaks in the
1800-1600 cm-1 region. The peaks at 1704 cm-1 and 1624 cm-1 are due to the C=O stretching of
the two carbonyl groups present in the structure of ciprofloxacin (Figure 2.1).18 The small peak at
3530 cm-1 is possibly a free hydroxyl stretching vibration, occasionally seen with carboxylic
acids.18 However, there is the clear lack of a carboxylic acid dimer, which would appear as a
broad, intense peak in the 3300-2500 cm-1 region.18
The brown line represents the spectra from SEC. The wide peak of low intensity from
3700 cm-1 to 3000 cm-1 is the result of intermolecular hydrogen bonding within the structure of
the sporopollenin.18 The peaks of medium intensity at 2928 cm-1 and 2856 cm-1 are from C – H
stretching vibrations.18 The peaks at 1132 cm-1 and 1003 cm-1 are due to C – O stretching
absorptions from the phenolic groups.18 While the peaks from the SEC begin to be obscured to
some extent by the ciprofloxacin HCl as additional encapsulations are performed, they are still
visible throughout. This indicates that the encapsulation procedure does not have a significant
effect on the molecular structure of the sporopollenin. Also, it is clear that the intensity of the
characteristic ciprofloxacin HCl peaks grow in comparison to the underlying baseline spectra of
the cleaned SEC with successive encapsulations, as was expected.
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Figure 2.11: FTIR Spectra of Ciprofloxacin HCl, SEC, and Selected Sequential
Encapsulations of Cipro@SEC.

2.3.2. XRD Analysis
A graph of the XRD spectra that were collected has been provided in Figure 2.12. As in
the FTIR spectra, the intensity of the characteristic ciprofloxacin HCl peaks increases with
sequential encapsulations. Also notable is that the overall strength of the broad and diffuse SEC
band within the sequential encapsulations decreases as the sample’s composition shifts from
being predominantly SEC to being predominantly ciprofloxacin HCl by mass. SEC, an
amorphous biopolymer, does not have any sharp diffraction peaks due to its lack of a crystal
structure.
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In the 1st Encapsulation spectra (red line), the peaks at 2θ values of 6.77°, 28.37°, and
40.94° do not directly correspond to the ciprofloxacin HCl spectrum that was collected.
Interestingly, they vanish by the 3rd Encapsulation. It was reported by Putra et. al. in 2020 that
ciprofloxacin HCl exhibits different diffraction bands, dependent on its hydration status.19 The
first anhydrous form of ciprofloxacin HCl they identified (AH1) corresponds with the peak at
6.77° and the peak at 28.37°. While the article in question ended their powder X-ray diffraction
scan at a 2θ value of 40°, it would not be unreasonable to expect that the small broad peak at
40.94° shown here would also correspond to the AH1 form of ciprofloxacin HCl they reported.
This hypothesis is further supported by their method of preparation of AH1: heating under
vacuum. While they used a temperature of 140 °C as opposed to the ~20 °C used here, their time
of vacuuming was only 30 minutes as opposed to the ~3 hours used in the present study. As to
why the AH1 peaks disappear with subsequent encapsulations, it may simply be a consequence of
insufficient vacuuming time to form the anhydrous form of ciprofloxacin HCl.

Figure 2.12: XRD Spectra of Cipro@SEC.
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2.3.3. Fluorescence Analysis
The excitation fluorescence spectra of the encapsulations have been provided in Figure
2.13, and the emission fluorescence spectra have been placed in Figure 2.14. The emission
spectra correspond to the emission of ciprofloxacin as observed in the literature.20 No suitable
literature reference could be found for the excitation spectra of solid ciprofloxacin HCl, but it is
evident that the shape of the 5th Encapsulation’s excitation and emission spectra closely
resembles the shape of the ciprofloxacin HCl spectra. As expected, with successive
encapsulations the ciprofloxacin HCl component of the Cipro@SEC grows in strength, although
the first encapsulation does not provide as much of an increase in signal as we would expect
when comparing it to the successive encapsulations.

Figure 2.13: Fluorescence Excitation Spectra of Cipro@SEC.
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Figure 2.14: Fluorescence Emission Spectra of Cipro@SEC.

2.3.4. SEM Analysis
To demonstrate the suitability of the pollen cleaning process for obtaining intact SEC
with an empty interior, SEM images of the raw pollen, the processed pollen (SEC), and processed
pollen that was ground in a mortar have been displayed in Figure 2.15. From comparing the raw
pollen to the processed pollen, it is clear that the cleaning procedure does not damage the shape or
overall structure of the exine capsule. In the ground pollen, it is possible to look inside the cavity
and verify that it is indeed empty of cellular material.
All SEM images that were collected of the sequential encapsulations of Cipro@SEC have
been placed in Figure 2.16. SEM images allow for the examination of the ciprofloxacin HCl that
appeared to be stuck on the outside of the encapsulated SEC, as was observed in the confocal
fluorescent images. The ciprofloxacin HCl appears to have crystallized in and around the fine
structure of the SEC, forming beautiful spikes and sheets of ciprofloxacin HCl on the outside of
the pollen. As expected, the relative amount of the external ciprofloxacin HCl increases with the
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number of sequential encapsulations. It is also clear that the encapsulation process does not
appear to have significantly affected the shape or structure of the SEC, once again demonstrating
the suitability of SEC for use as a robust encapsulators. Unfortunately, SEM analysis does not
allow for the inspection of the internal cavity of the Cipro@SEC, and so another method must be
used: confocal fluorescent microscopy.

Figure 2.15: A) Raw Pollen. B) Processed Pollen (SEC). C) SEC, Ground in a Mortar.
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Figure 2.16: SEM Images: 0) SEC. 1) 1st Encapsulation. 2) 2nd Encapsulation. 3) 3rd
Encapsulation. 4) 4th Encapsulation. 5) 5th Encapsulation. A) 400x. B) 3000x, Top Surface.
C) 3000x, Bottom Surface.
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Figure 2.16 (cont.): SEM Images: 0) SEC. 1) 1st Encapsulation. 2) 2nd Encapsulation. 3)
3rd Encapsulation. 4) 4th Encapsulation. 5) 5th Encapsulation. A) 400x. B) 3000x, Top
Surface. C) 3000x, Bottom Surface.
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Figure 2.16 (cont.): SEM Images: 0) SEC. 1) 1st Encapsulation. 2) 2nd Encapsulation. 3)
3rd Encapsulation. 4) 4th Encapsulation. 5) 5th Encapsulation. A) 400x. B) 3000x, Top
Surface. C) 3000x, Bottom Surface.
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Figure 2.16 (cont.): SEM Images: 0) SEC. 1) 1st Encapsulation. 2) 2nd Encapsulation. 3)
3rd Encapsulation. 4) 4th Encapsulation. 5) 5th Encapsulation. A) 400x. B) 3000x, Top
Surface. C) 3000x, Bottom Surface.
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Figure 2.16 (cont.): SEM Images: 0) SEC. 1) 1st Encapsulation. 2) 2nd Encapsulation. 3)
3rd Encapsulation. 4) 4th Encapsulation. 5) 5th Encapsulation. A) 400x. B) 3000x, Top
Surface. C) 3000x, Bottom Surface.
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Figure 2.16 (cont.): SEM Images: 0) SEC. 1) 1st Encapsulation. 2) 2nd Encapsulation. 3)
3rd Encapsulation. 4) 4th Encapsulation. 5) 5th Encapsulation. A) 400x. B) 3000x, Top
Surface. C) 3000x, Bottom Surface.
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2.3.5. Confocal Fluorescence Microscopy
All collected confocal fluorescence images have been placed in Figure 2.18. Samples
were imaged in 1-octanol as described previously, and the exact same camera settings were used
for each set of images. Ciprofloxacin HCl primarily appears in the blue region, while the structure
of the pollen is most visible in the “B) Green, Red” images. An image taken in water has also
been provided in Figure 2.17, to demonstrate why water is not a suitable solvent for confocal
analysis of Cipro@SEC.
When comparing the images of the raw pollen (Figure 2.18.R) and the empty SEC
(Figure 2.18.0), it is clear that the cleaning process effectively removes the material from the
inside of the pollen, leaving behind a clean, empty Sporopollenin Exine Capsule. In the 1st
Encapsulation images (Figure 2.18.1), the initial “staining” of the pollen with the fluorescent
ciprofloxacin HCl is clearly seen, which may play a role in the less-than-expected signal observed
for the 1st Encapsulation in the fluorescence spectra. From the 2nd Encapsulation through the 5th
Encapsulation, the amount of ciprofloxacin inside the SEC steadily increases until it appears that
the SEC is completely filled with ciprofloxacin HCl in the 5th Encapsulation. It is clear that the
described method of encapsulation successfully places ciprofloxacin HCl into the inner cavity of
the SEC.
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Figure 2.17: Confocal Image of Cipro@SEC in Water. Ciprofloxacin HCl Dissolves Readily
in Water, Providing the Strong Blue Fluorescence in This Image.
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Figure 2.18: Confocal Fluorescent Images: R) Raw Pollen. 0) SEC. 1) 1st Encapsulation. 2) 2nd
Encapsulation. 3) 3rd Encapsulation. 4) 4th Encapsulation. 5) 5th Encapsulation. A) 3 Lasers: Blue,
Green, Red. B) 2 Lasers: Green, Red. C) 1 Laser: Blue. D) 1 Laser: Green. E) 1 Laser: Red.
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Figure 2.18 (cont.): Confocal Fluorescent Images: R) Raw Pollen. 0) SEC. 1) 1st Encapsulation. 2)
2nd Encapsulation. 3) 3rd Encapsulation. 4) 4th Encapsulation. 5) 5th Encapsulation. A) 3 Lasers:
Blue, Green, Red. B) 2 Lasers: Green, Red. C) 1 Laser: Blue. D) 1 Laser: Green. E) 1 Laser: Red.
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Figure 2.18 (cont.): Confocal Fluorescent Images: R) Raw Pollen. 0) SEC. 1) 1st Encapsulation. 2)
2nd Encapsulation. 3) 3rd Encapsulation. 4) 4th Encapsulation. 5) 5th Encapsulation. A) 3 Lasers:
Blue, Green, Red. B) 2 Lasers: Green, Red. C) 1 Laser: Blue. D) 1 Laser: Green. E) 1 Laser: Red.
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Figure 2.18 (cont.): Confocal Fluorescent Images: R) Raw Pollen. 0) SEC. 1) 1st Encapsulation. 2)
2nd Encapsulation. 3) 3rd Encapsulation. 4) 4th Encapsulation. 5) 5th Encapsulation. A) 3 Lasers:
Blue, Green, Red. B) 2 Lasers: Green, Red. C) 1 Laser: Blue. D) 1 Laser: Green. E) 1 Laser: Red.
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Figure 2.18 (cont.): Confocal Fluorescent Images: R) Raw Pollen. 0) SEC. 1) 1st Encapsulation. 2)
2nd Encapsulation. 3) 3rd Encapsulation. 4) 4th Encapsulation. 5) 5th Encapsulation. A) 3 Lasers:
Blue, Green, Red. B) 2 Lasers: Green, Red. C) 1 Laser: Blue. D) 1 Laser: Green. E) 1 Laser: Red.
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Figure 2.18 (cont.): Confocal Fluorescent Images: R) Raw Pollen. 0) SEC. 1) 1st Encapsulation. 2)
2nd Encapsulation. 3) 3rd Encapsulation. 4) 4th Encapsulation. 5) 5th Encapsulation. A) 3 Lasers:
Blue, Green, Red. B) 2 Lasers: Green, Red. C) 1 Laser: Blue. D) 1 Laser: Green. E) 1 Laser: Red.
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Figure 2.18 (cont.): Confocal Fluorescent Images: R) Raw Pollen. 0) SEC. 1) 1st Encapsulation. 2)
2nd Encapsulation. 3) 3rd Encapsulation. 4) 4th Encapsulation. 5) 5th Encapsulation. A) 3 Lasers:
Blue, Green, Red. B) 2 Lasers: Green, Red. C) 1 Laser: Blue. D) 1 Laser: Green. E) 1 Laser: Red.
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2.4. Conclusions
In summary, visual inspection of the encapsulation process showed that the final
Cipro@SEC was a fine powder with a light brown color, with the color lightening slightly with
each successive encapsulation. This was in agreement with the results from FTIR analysis, in
which the strength of the ciprofloxacin HCl peaks increased with successive encapsulations. XRD
analysis and analysis of fluorescence spectra provided similar results. Analysis of each
encapsulation by SEM imagery demonstrated that the exterior surface of the SEC contained
various spikes and shards of crystallized ciprofloxacin HCl, with the relative quantity increasing
with each successive encapsulation.
Finally, through the application of confocal fluorescence microscopy to each successive
encapsulation, it became clear that the described method was suitable for encapsulating
ciprofloxacin HCl into the inner cavity of SEC.
Finding a suitable procedure for washing away only the external ciprofloxacin HCl while
leaving the internal antibiotic undisturbed was determined to be outside the scope of this work,
but could be the subject of future research. The presence of the external crystals of ciprofloxacin
HCl is unfortunate, but it may not negatively affect the use of the Cipro@SEC for the
manufacture of the novel polymer composites. This will be explored in Chapter 3.
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Chapter 3. SYNTHESIS OF [CEL+CS] COMPOSITES WITH CIPRO@SEC

3.1. Background
3.1.1. Cellulose and Chitosan
As detailed in Chapter 1, Cellulose is a linear polysaccharide composed of glucose chains
of varying lengths.1 The glucose units are linked to each other through (β-1,4-glucan) covalent
bonds.1 A diagram of the polymer chain is shown below in Figure 3.1.
Figure 3.1: Structure of a Single Chain of Cellulose.1

Figure 3.2: Intramolecular and Intermolecular Hydrogen Bonds of Cellulose.2

Cellulose chains are linked together into a network of intramolecular and intermolecular
hydrogen bonds as shown above in Figure 3.2.2 This provides cellulose with high strength and
durability, but also renders it virtually insoluble in water or other common organic solvents.3
Solvent systems that can overcome the hydrogen bonds of cellulose exist, but these generate
hazardous wastes and are difficult to recover for reuse.3
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Chitosan is a biopolymer similar to cellulose that is commonly derived via alkaline
deacetylation of chitin, a biopolymer that is the second-most abundant biopolymer on Earth.4
Chitosan’s structure is a linear polysaccharide with β-(1-4)-linked 2-amino-2-deoxy-D-glucose
and 2-acetamido-deoxy-D-glucose monomers.4 The structure of this copolymer is shown in
Figure 3.3. Chitosan is soluble in dilute acidic solutions, such as acetic acid.5

Figure 3.3: Structure of a Single Chain of Chitosan. On the Left, the Acetylated Monomer;
on the Right, the Deacetylated Monomer.5

Chitosan has several unique properties that make it attractive for use in medical
applications. Chitosan is antibacterial5,6, antifungal5, mucoadhesive7, hemostatic8, promotive of
wound healing9, and has even been used for drug delivery5. Chitosan as a biopolymer is also
biocompatible and biodegradable.5,10 However, chitosan is not a perfect biopolymer. Chitosan is
structurally weak, having a poor tensile strength in comparison to other biopolymers such as
cellulose.11 It has also been shown to swell when wet.12 Because of this, several existing
applications of chitosan graft the polymer to other synthetic polymers to provide the structural
strength that chitosan lacks.13-15
As described in Chapter 1, ionic liquids can dissolve both cellulose and chitosan. One
ionic liquid in particular, 1-butyl-methylimidazolium chloride, has been shown to be able to
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dissolve both cellulose2,16 and chitosan17 and has been used previously to produce [CEL+CS]
hybrid composites11,18,19.
3.1.2. Ciprofloxacin
As described previously in Chapter 1 and Chapter 2, ciprofloxacin is a broad-spectrum
antibiotic that targets both Gram positive and Gram negative bacteria.20 In order to protect it from
the unfavorable environments of the synthetic procedure, ciprofloxacin hydrochloride was
encapsulated in sporopollenin exine capsules in order to produce Cipro@SEC.21 Due to
ciprofloxacin hydrochloride’s solubility in water, the gelification and washing steps of the
synthetic procedure were modified to use 2-propanol instead of water.22,23 The encapsulated
ciprofloxacin HCl (Cipro@SEC), whose preparation and characterization were described in detail
in Chapter 2, was used as the source of ciprofloxacin in this study.
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3.2. Materials and Methods
3.2.1. Chemicals
Cellulose microcrystalline powder and chitosan powder were purchased from SigmaAldrich and used as received. 1-chlorobutane and 1-methylimidazole were obtained from Alfa
Aesar and used to prepare the [BMIM+Cl-] ionic liquid solvent as previously described, and as
will be described in detail in a later section.24,25 The 1-methylimidazole was further purified by
vacuum distillation before being used in the synthesis. Acetonitrile was purchased from Acros
Organics. Sporopollenin exine capsules encapsulated with ciprofloxacin HCl (Cipro@SEC) were
produced as described in Chapter 2. 2-propanol (99.9%) was purchased from Honeywell for
washing the composites and was distilled as necessary. The temperature of the liquid in the 2propanol distillation flask was consistently at 82.6 °C, the boiling point of pure 2-propanol.
3.2.2. Instruments
FTIR spectra, XRD spectra, Fluorescence spectra, and SEM images were collected on the
same instruments and as described in Chapter 2.
UV-Vis spectra were collected on a PerkinElmer Lambda 35 UV/VIS Spectrometer.
Samples were scanned from 700-200 nm, and the scan rate was 480 nm/min. The slit width was 1
nm. UV-Vis spectra were primarily used as qualitative quality control analysis, so there is not a
formal UV-Vis analysis section in the Results and Discussion.
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3.2.3. Synthesis of [CEL+CS] Composites with Cipro@SEC
3.2.3.1. Synthesis of [BMIM+Cl-] Ionic Liquid Solvent
The [BMIM+Cl-] ionic liquid solvent was synthesized as previously described.24,25
Briefly, a 1.05:1 ratio of 1-chlorobutane to 1-methylimidazole were mixed together in acetonitrile
solvent in an ice-bath. Total acetonitrile volume was slightly more than the total volume of the 1chlorobutane and 1-methylimidazole reactants. The mixture was stirred vigorously at reflux (80
°C) for 4 days. A 5% excess of 1-chlorobutane was used to ensure complete reaction of the 1methylimidazole. The reacted mixture was heated at 90 °C under vacuum in a rotary evaporator
to remove the acetonitrile solvent. The ionic liquid was then recrystallized three times in acetone,
heated at 90 °C under vacuum in a rotary evaporator to remove the acetone, and followed by
vigorous stirring at 130 °C under vacuum to remove all residual traces of other solvents.
3.2.3.2. Synthesis of [CEL+CS] Composites
Polymer composites consisting of a mixture of cellulose and chitosan polymers were
synthesized similar to a method described in the literature.11 A summary of the synthetic process
has been displayed in Figure 3.4. A weighed amount of [BMIM+Cl-] ionic liquid was heated to
100 °C with vigorous stirring. 3% w/w cellulose was then added slowly to avoid clumping. After
about an hour, the cellulose had completely dissolved. An image of the cellulose dissolution
process is shown in Figure 3.5. The ionic liquid was then heated to 120 °C and 3 additions of 1%
w/w chitosan were added. The chitosan was allowed to completely dissolve between additions,
usually taking about an hour each time before no undissolved chitosan powder was visible. The
composite mixture was then stirred at the maximum rate possible, according to the strength of the
stir plate, as the mixture thickens at 120 °C for at least 5 hours. An image of the
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Figure 3.4: Schematic of Synthetic Process for the Production of [CEL+CS+XX%
Cipro@SEC] Composites.

composite at the conclusion of the thickening process is shown in Figure 3.6. The temperature of
the composite is then reduced to 90 °C, and the appropriate amount of Cipro@SEC is added to
the composite. This was followed by vigorous stirring by hand for 3 minutes to make the desired
[CEL+CS+XX% Cipro@SEC] composite (20%, 30%, 40%, 50%, or 60% w/w based on the total
weight of the polymer added). The composite was then cast into PTFE molds on top of Mylar
film, 3.2 g of composite per film. Typically, 21 g of [BMIM+Cl-] was used to enable the
sequential casting of 4 molds of 3.2 g each from the same flask. The composites were spread out
into the mold with a small stainless-steel spatula. The molds were held together with mini binder
clips, since it was found that the tape used in a previous method24,25 partially dissolved in the 2propanol atmosphere utilized in the gelification step. The composite then was covered with a
PTFE mesh in an effort to keep swelling to a minimum during the gelification process, which will
be described in a later section. An image of the Teflon mold before the addition of the composite
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is shown in Figure 3.7, and an image of the mold completed with the Teflon mesh is shown in
Figure 3.8.
Figure 3.5: Dissolution of 3% w/w Cellulose in [BMIM+Cl-].

Figure 3.6: [CEL+CS] Composite before Addition of Cipro@SEC.
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Figure 3.7: Teflon Mold and Mylar Backing, Held Together with Mini Binder Clips.

Figure 3.8: Teflon Mesh-Covered Composite (in Gelification Chamber).
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3.2.3.3. Gelification of Composites
The [CEL+CS+Cipro@SEC] composites were then immediately placed in a desiccator
set up as shown in Figure 3.9 and Figure 3.10 and allowed to gelify for 4 days. Briefly, a
desiccator was cleaned and emptied. A glass bowl of 9” diameter was filled with freshly
regenerated indicating silica gel bead desiccant (baked at 110 °C overnight, per manufacturer’s
directions) and placed in the desiccator. 1 L of 2-propanol was then added to the desiccator
around the bowl. The desiccator’s ceramic plate insert was placed on top of the bowl, and the
bowl was adjusted so that the plate was level. Pieces of filter paper were then placed around the
inner circumference of the desiccator, partially submerged in the solvent, in order to provide a
saturated atmosphere. A 100 mL beaker was filled with 80 mL of 2-propanol, fitted with a cut
piece of filter paper, and placed in the center of the ceramic plate in order to further ensure a
saturated atmosphere. The desiccator was then sealed and connected to a vacuum for 15 minutes
to remove the air. Finally, the desiccator was attached to a gas-trap filled with 2-propanol. The
vacuum was slowly released, and the air was bubbled through the 2-propanol gas-trap in an effort
to keep the inner atmosphere as saturated with 2-propanol as possible while simultaneously
keeping the internal pressure at atmospheric pressure. During the duration of the gelification
process, the desiccator’s vent was left attached to the trap in order to ensure a reasonably stable
pressure.
One concentration of composite (40% Cipro@SEC) was prepared both with the
desiccator as described above, and with a desiccator that had the filter paper and the small beaker
of 2-propanol removed. It was found that this setup took significantly longer to fully gelify, a full
8 days instead of 4 days.

63
Figure 3.9: Schematic of Gelification Desiccator.

Figure 3.10: Top-Down View of Gelification Chamber.
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3.2.3.3.1. Previous Work
In previous work, the water gelification of these composites from atmospheric exposure
was investigated. It was observed that an insufficient amount of ciprofloxacin HCl was present in
the final composites according to XRD measurements (data not shown), even when being washed
with 2-propanol instead of with water. It was determined that the ciprofloxacin HCl was exiting
the composite via the gelification fluid. Gelification fluid is the liquid that is pushed out onto the
surface of the composite as the polymer matrix is gelifiying, as can be seen in Figure 3.11. The
gelification solvent displaces the ionic liquid and allows the polymers to solidify in the shape of
the mold. In this case, water from the atmosphere and the ionic liquid partially dissolved the
ciprofloxacin HCl and carried a portion of it away from the bulk composite. When the composites
were gelified in a 2-propanol atmosphere instead of with humidity from the air, the gelification
fluid had a substantially lower concentration of ciprofloxacin HCl, and this was confirmed by a
stronger ciprofloxacin HCl signal from XRD. The UV-Vis spectra shown in Figure 3.12 shows
the different concentration of ciprofloxacin HCl in the gelification fluid that was observed. In this
figure, one drop of the gelification fluid was diluted to 10 mL with water, then scanned. A
composite with and without Cipro@SEC was gelified in water to establish the difference in the
UV-Vis spectra that could be expected from the presence of ciprofloxacin HCl, and a composite
with Cipro@SEC was gelified in 2-propanol to determine the effect of the altered gelification
solvent. To establish a baseline, one drop of 2-propanol was diluted to 10 mL with water.
After making the decision to gelify composites in 2-propanol, efforts focused on
optimizing the gelification chamber. It was observed that when the gelification chamber was
insufficiently dry, the gelifiying composites “bulged” upwards. It was found that the
configuration of the fifth iteration of the chamber, shown in Figure 3.9 and Figure 3.10, produced
acceptable composites that were free of swelling. Further analysis of the swelling is provided in a
later section.
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Figure 3.11: Gelification Fluid Accumulation on the Surface of the Composite.

Figure 3.12: UV-Vis Spectra of Gelification Fluid using Different Gelification Solvents
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3.2.3.4. Washing of Composites
At the end of the day on the 4th day after the composites were placed in the gelification
desiccator, the composites were removed and placed in a 2 L beaker to wash in 1800 mL of 2propanol in order to remove the [BMIM+Cl-] solvent from the gelified composite. As discussed in
the introduction, water cannot be used for the washing step since ciprofloxacin HCl is water
soluble. An example of such a beaker is shown in Figure 3.13. Inside the beaker was a magnetic
stir bar, a small ceramic desiccator insert, a circular section of PTFE mesh, the composite to be
washed, and finally the 1.8 L of 2-propanol. The top of the beaker was tightly covered with
aluminum foil to prevent evaporation of the solvent and reduce contamination with water from
humidity in the air. Parafilm can also be used, but it was not durable enough to survive for several
days of washing and was deemed impractical for this study.

Figure 3.13: Washing Beaker.
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After being placed in the first 2-propanol bath, the solvent was drained and replaced after
1-2 hours. The purpose of this step is to remove the [BMIM+Cl-] from the gelification fluid that
clung to the surface of the composite and to provide a clean 2-propanol bath for overnight
washing. The solvent bath was then changed once daily for an additional 3 days. If the solvent
was free of residual [BMIM+Cl-] solvent on the 4th day as verified by UV-Vis spectra, the
composites are removed from the solvent bath and dried.
3.2.3.5. Drying of Composites
The washed composites were sandwiched between filter paper and paper towels as
illustrated by the schematic in Figure 3.14 and the image in Figure 3.15, followed by the
application of a lead brick. In order from bottom to top, the components are: paper towel, filter
paper, washed composites, filter paper, paper towel, lead brick. Thusly arranged, the composites
are then dried under vacuum at room temperature for 4 hours. After the first 60-90 minutes, it is
necessary to remove frozen 2-propanol from the liquid nitrogen trap. If left uncleaned the trap
will clog within 2 hours, causing a drop in vacuum strength. The function of the lead brick is to
force the composites to remain flat during the drying process. If left unrestrained, the composites
tended to curl up while drying.

Figure 3.14: Schematic of the Arrangement for Drying Composites.
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Figure 3.15: Arrangement for Drying Composites. Lead Brick is Shown Underneath.
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3.3. Results and Discussion
3.3.1. Visual Analysis
3.3.1.1. Observations from Gelified Composites
Upon visual inspection of the composites, the first noticeable difference between
composites gelified with 2-propanol and those gelified with water (studied previously, data not
shown) is that the 2-propanol composites are stiffer and denser. They also have a slightly shorter
length and width than the water composites, as shown in Table 3.1.

Table 3.1: Comparison of Similar Composites Pre-Drying, Gelified with Different Solvents.
Measurements Accurate to 1/20 mm.

Solvent Type
Water
2-Propanol
Percent Difference

Length Width
40.30 mm 36.00 mm
38.95 mm 35.40 mm
~3%

~2%

This shrinkage is likely the cause of the unusual swelling that was observed when the
composites were not sufficiently protected from exposure to humidity during the gelification
process, as shown in Figure 3.16 and Figure 3.17. The likely mechanism for the formation of this
“bulge” on the top surface is that the top layer of the composite gelified with trace water in the
gelification chamber, while the rest of the composite underneath the “water” layer gelifies with 2propanol after the residual amount of water has been exhausted.
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Figure 3.16: Swelling of the Composite (Bulge Formation).

Figure 3.17: Swelling of the Composite (Bulge Formation). Slight Blurring of the Image
from being Taken through the Wall of a Desiccator.

Evidence for this arrangement of gelification regions is shown in Figure 3.18, where a
swelled composite was cut in half. It was observed that the composite had two distinct layers: the
top layer was lighter in color and less dense, similar to water gelified composites, while the
bottom layer (nearest the Mylar) was darker in color due to the higher density that was typical of
2-propanol gelified composites. The shrinking 2-propanol region on the bottom seems to pull the
composite in on itself, pushing up the middle of the composite into the bulge that was observed.
The bulge in the indicated figure is especially accentuated due to being air-dried, but the analysis
provided is based on observations from the undried composite. The desiccated 2-propanol
atmosphere as shown in Figure 3.9 and Figure 3.10 is able to effectively isolate the composites
from water during the gelification process, preventing the formation of any bulges.
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Figure 3.18: Evidence for the Formation of Two Distinct Gelification Regions when
Improperly Gelified.

It was also observed that composites that were well-protected from water tended to
adhere to the Mylar film while shrinking, producing a trapezoidal shape when viewed from the
correct angle, as shown in Figure 3.19. The top surface contracts freely, the bottom does not.

Figure 3.19: Slight Trapezoidal Shape of the Composite, Properly Gelified.

3.3.1.2. Observations from Dried Composites
Selected photographs of the properly gelified, washed, and dried composites have been
placed in Figure 3.20, both in their gelified form and in their dried form. The composites are
homogeneous in appearance, indicating that 3 minutes of thorough mixing is sufficient to
distribute the Cipro@SEC throughout the composite. As expected, the shade of the composite
grows darker as the proportion of Cipro@SEC increases.
No visual difference was seen between the [CEL+CS+40% Cipro@SEC] composite that
was gelified in 4 days and the composite that was gelified for 8 days.
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Figure 3.20: Photographs of [CEL+CS+XX% Cipro@SEC] Composites After Gelification,
and After Being Dried.

20% Gel

20% Dry

40% Gel

40% Dry

60% Gel

60% Dry

3.3.2. FTIR Analysis
A graph of the FTIR spectra taken as described has been provided in Figure 3.21. To
guide the eye, vertical dotted lines have been provided for selected peaks: magenta for
[BMIM+Cl-] peaks at 3041 cm-1, 1567 cm-1, and 1170 cm-1, and cyan for the 2-propanol peaks at
2970 cm-1, 951 cm-1, 817 cm-1. Neither the characteristic peaks of [BMIM+Cl-] nor of 2-propanol
are visible in either the blank composite ([CEL+CS]), composite with empty SEC added
([CEL+CS+50% SEC]), or in the composite with Cipro@SEC added ([CEL+CS+50%
Cipro@SEC]). This clearly indicates that washing the composites in 2-propanol for 3 days is
sufficient to completely remove the ionic liquid solvent from the gelified composites. This also
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indicates that drying the composites under vacuum for several hours is sufficient to remove the 2propanol, yielding composites that are made up of only cellulose, chitosan, and Cipro@SEC.
Figure 3.21: FTIR Spectra of the [BMIM+Cl-] Ionic Liquid and the 2-Propanol Washing
Solvent as Well as Other Selected Composites. Labels with a * Indicate a Spectrum that has
been Appropriately Scaled.

Figure 3.22 displays the spectra of the cellulose and chitosan powders that were used in
the production of the composites, which are also displayed. Due to their similar structure,
cellulose and chitosan share several regions of interest. Intermolecular O – H stretching is visible
from 3600 – 3000 cm-1, C – H stretch from 3000 – 2800 cm-1, and – O – ether vibration modes
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from 1190 – 850 cm-1.11,18,19,26-31 These three characteristic regions are also present in the final
dried composites in the same manner as in the literature11,18,19,26-30, providing strong evidence that
the cellulose and chitosan were successfully regenerated by the synthetic process employed here.
The spectra of the [CEL+CS], [CEL+CS+50% SEC], and [CEL+CS+50% Cipro@SEC] dried
composites are also provided in Figure 3.22 in order to demonstrate that the incorporation of
additives such as SEC or Cipro@SEC does not hinder the regeneration of the cellulose and
chitosan into the final dried composites when compared to the “blank” sample, [CEL+CS].

Figure 3.22: FTIR Spectra of Cellulose, Chitosan, and Selected Composites. Labels with a *
Indicate a Spectrum that has been Appropriately Scaled.

Being derived from a partial deacetylation of chitin, chitosan has two different groups in
place of the hydroxyl group found in cellulose, as shown in Figure 3.23. The characteristic peaks
that result from the amide and the amine substitutions are also seen in Figure 3.22, denoted by
vertical red dotted lines. Weak asymmetrical and symmetrical N – H stretching vibrations are
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present from 3400 – 3250 cm-1, with the very weak peaks indicated at 3349 cm-1 and 3292
cm-1.11,18,19,26,27,29-31 Stretching vibrations of the C=O carbonyl are found at 1653 cm-1 in the amide
I band.11,18,19,26-32 Scissoring vibration of the N – H primary amine is seen at 1579 cm-1, and at
1374 cm-1 is found the symmetrical bending vibration of CH3.11,19,27,28,30,31 Finally, the C – N
stretching of the amide III band has a peak at 1309 cm-1.11,19,26,27,29,30,32
Figure 3.23: Structure of a Single Chain of Chitosan.33

Figure 3.24 displays the spectrum of Cipro@SEC and [CEL+CS+60% Cipro@SEC] as a
sample composite to illustrate the lack of Cipro@SEC peaks in the FTIR spectra. None of the
characteristic Cipro@SEC peaks were visible in any of the Cipro@SEC composites. This is not
surprising, since the depth of penetration of the evanescent wave used in the FTIR-ATR method
is only about 2 µm according to the manufacturer of the ATR accessory.34 It is relatively unlikely
that ciprofloxacin HCl remains on the surface of the composite within this depth, not only since it
is weakly soluble in 2-propanol23, but also since the majority of ciprofloxacin HCl is sequestered
within the pollen and likely to be out of reach of the evanescent wave. This sequestration is what
allows the ciprofloxacin HCl to be both incorporated into the composites and survive the
manufacturing procedure.
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Overall, no significant differences were observed in the FTIR spectra from the various
concentrations of Cipro@SEC composites that were prepared and gelified for 4 days. The
[CEL+CS+40% Cipro@SEC] composite that was gelified for both 4 days and 8 days also
displayed no significant differences between the sample sets.

Figure 3.24: FTIR Spectra of Cipro@SEC and [CEL+CS+60% Cipro@SEC].

3.3.3. XRD Analysis
A graph of the XRD spectra that were collected of the polymer constituents, cellulose and
chitosan, as well as of SEC, [CEL+CS] composite, and [CEL+CS+50% SEC] composite have
been displayed in Figure 3.25. Microcrystalline cellulose has diffraction peaks at 2θ values of
15.05°, 16.61°, 22.82°, and 34.97°, for the (101),

, (002), and (040) planes, respectively.35,36

Chitosan’s diffraction peaks are at 2θ values of 10.49°, 11.42°, and 20.39°, for the (010), (100),
and (020) planes, respectively.37 The cellulose peaks have been indicated with vertical green
dotted lines, and the chitosan peaks with red dotted lines. It is readily apparent that the polymers
were dissolved by the [BMIM+Cl-] ionic liquid solvent since the crystal structure in the original
polymers is absent in the dried composites. Instead, the dried composites exhibit a broad, diffuse
scattering pattern that corresponds to the XRD spectra of similarly prepared cellulose and
chitosan composites in the literature.11,18,19 As can also be seen in Figure 3.25, the addition of the
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amorphous SEC does not significantly alter the internal structure of the [CEL+CS+50% SEC]
composite when compared to the [CEL+CS] composite; the [CEL+CS+50% SEC] spectrum is
essentially an addition of the [CEL+CS] spectrum to the [SEC] spectrum.

Figure 3.25: XRD Spectra of Cellulose, Chitosan, and Selected Composites.
Crystallographic Planes are Labeled Where Applicable.

A graph of the XRD spectra that were collected of the [CEL+CS+XX% Cipro@SEC]
composites is shown in Figure 3.26, along with the spectra of ciprofloxacin, ciprofloxacin HCl,
and Cipro@SEC. Most peaks in the [CEL+CS+Cipro@SEC] composites are explainable by
referencing either the Cipro@SEC that was incorporated into the composite, or the as-received
neutral form of ciprofloxacin. Small peaks at a 2θ of 7.58° and 42.23° do not correspond to either
the spectrum of Cipro@SEC or of ciprofloxacin. However, similar to what was mentioned in
Chapter 2, the peak at 7.58° corresponds to an anhydrous crystal structure of ciprofloxacin HCl
that was discovered by Putra et. al. in 2020.38 While their investigation ended their XRD scan at a
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2θ value of 40°, it would not be unreasonable to speculate that the small peak at 42.23° would
also correspond to an anhydrous form of ciprofloxacin HCl. Given that the [CEL+CS+XX%
Cipro@SEC] composites are dried under vacuum and under the pressure of a lead brick for
several hours, it is certainly plausible that some of the ciprofloxacin HCL adopted an anhydrous
crystal structure.
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Figure 3.26: XRD Spectra of Ciprofloxacin, Ciprofloxacin HCl, Cipro@SEC, and Selected
[CEL+CS+XX% Cipro@SEC] Composites.
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3.3.4. Fluorescence Analysis
The excitation fluorescence spectra of selected [CEL+CS+XX% Cipro@SEC]
composites have been provided in Figure 3.27, and the corresponding emission fluorescence
spectra have been placed in Figure 3.28. The shape of the excitation spectra of the composites
results from a simple addition of three distinct components: Cipro@SEC, ciprofloxacin, and a
component with a peak between 280-300 nm. A literature search revealed that this third
component corresponds well to ciprofloxacin solution at a pH of ~4.39-41 The emission spectra
appears to result from an addition of the Cipro@SEC signal to the ciprofloxacin signal. Evidence
for a third component was not found in the emission spectra. In both the excitation and the
emission spectra, the non-ciprofloxacin components (cellulose, chitosan, and SEC, represented by
the [CEL+CS+50% SEC] spectrum) insignificantly contributed to the overall strength of the
fluorescence signal.
It is easily apparent that the [CEL+CS+30% Cipro@SEC] composite has stronger
fluorescence than even the [CEL+CS+60% Cipro@SEC] composite. As mentioned in Chapter 1,
it is known that [BMIM+Cl-] is hygroscopic, and that ciprofloxacin HCl is soluble in water. The
[CEL+CS+30% Cipro@SEC] composite was made with freshly dried ionic liquid, while due to
time constraints the other composites were not. It is likely that the small amount of water
absorbed by the ionic liquid over time was able to remove more of the ciprofloxacin HCl from the
other composites than was the case for the [CEL+CS+30% Cipro@SEC] composite. This further
demonstrates the importance of taking all available steps to prevent the composites from coming
in contact with water during their synthesis, gelification, washing, and drying.
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Figure 3.27: Fluorescence Excitation Spectra of [CEL+CS+XX% Cipro@SEC]. Labels with
a * Indicate a Spectrum that has been Appropriately Scaled.
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Figure 3.28: Fluorescence Emission Spectra of [CEL+CS+XX% Cipro@SEC]. Labels with
a * Indicate a Spectrum that has been Appropriately Scaled.

83
3.3.5. SEM Analysis
All SEM images that were collected of the [CEL+CS+Cipro@SEC] composites have
been placed in Figure 3.29. In the [CEL+CS] composites images, we see the small surface
irregularities that are unavoidable with this method of casting. However, the composite as a
whole has a smooth and homogenous surface. In the [CEL+CS+50% SEC] composites, we see
the densely arranged SEC on the surface of the composite. From this, we can see that the
composite synthesis process does not damage the structure of the SEC. It is also clear that the
pollen grains are substantially covered by the [CEL+CS] polymer composite, which is contrary to
what had been observed previously for [CEL] composites.24 As the concentration of Cipro@SEC
increases from 20%-60%, the relative abundance of visible pollen also increases. The
ciprofloxacin HCl that had been on the outside of the Cipro@SEC is no longer present, having
been dissolved by the ionic liquid during the synthesis of the composites. A portion was then
washed away by the 2-propanol washing baths. Some of the external ciprofloxacin HCl may still
remain in the composite, possibly yielding the other peaks in the XRD and fluorescence spectra
as described earlier.
The [CEL+CS+40% Cipro@SEC] that was gelified for 8 days seems to have
substantially fewer pollen grains exposed on the surface of the polymer composite than the
composites that were gelified for 4 days. The pollen is still present, but it is underneath the
surface of the composite as opposed to poking out through the surface. The exact mechanism for
this difference is not known at this time. However, it might be the case that the more rapid
gelification process partially expels the pollen grains while a slower gelification locks them in
place within the bulk composite. The composites may be affected in other ways by the speed of
gelification, but such study is outside the scope of this work.
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Figure 3.29: SEM Images: 0) [CEL+CS]. 50SEC) [CEL+CS+50% SEC]. 20)
[CEL+CS+20% Cipro@SEC]. 30) [CEL+CS+30% Cipro@SEC]. 40F) [CEL+CS+40%
Cipro@SEC] FAST. 40S) [CEL+CS+40% Cipro@SEC] SLOW. 50) [CEL+CS+50%
Cipro@SEC]. 60) [CEL+CS+60% Cipro@SEC]. A) 200x. B) 400x. C) 1000x. D) 3000x.

0.A

0.B

0.C

0.D
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Figure 3.29 (cont.): SEM images: 0) [CEL+CS]. 50SEC) [CEL+CS+50% SEC]. 20)
[CEL+CS+20% Cipro@SEC]. 30) [CEL+CS+30% Cipro@SEC]. 40F) [CEL+CS+40%
Cipro@SEC] FAST. 40S) [CEL+CS+40% Cipro@SEC] SLOW. 50) [CEL+CS+50%
Cipro@SEC]. 60) [CEL+CS+60% Cipro@SEC]. A) 200x. B) 400x. C) 1000x. D) 3000x.

50SEC.A

50SEC.B

50SEC.C

50SEC.D
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Figure 3.29 (cont.): SEM images: 0) [CEL+CS]. 50SEC) [CEL+CS+50% SEC]. 20)
[CEL+CS+20% Cipro@SEC]. 30) [CEL+CS+30% Cipro@SEC]. 40F) [CEL+CS+40%
Cipro@SEC] FAST. 40S) [CEL+CS+40% Cipro@SEC] SLOW. 50) [CEL+CS+50%
Cipro@SEC]. 60) [CEL+CS+60% Cipro@SEC]. A) 200x. B) 400x. C) 1000x. D) 3000x.

20.A

20.B

20.C

20.D
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Figure 3.29 (cont.): SEM images: 0) [CEL+CS]. 50SEC) [CEL+CS+50% SEC]. 20)
[CEL+CS+20% Cipro@SEC]. 30) [CEL+CS+30% Cipro@SEC]. 40F) [CEL+CS+40%
Cipro@SEC] FAST. 40S) [CEL+CS+40% Cipro@SEC] SLOW. 50) [CEL+CS+50%
Cipro@SEC]. 60) [CEL+CS+60% Cipro@SEC]. A) 200x. B) 400x. C) 1000x. D) 3000x.

30.A

30.B

30.C

30.D
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Figure 3.29 (cont.): SEM images: 0) [CEL+CS]. 50SEC) [CEL+CS+50% SEC]. 20)
[CEL+CS+20% Cipro@SEC]. 30) [CEL+CS+30% Cipro@SEC]. 40F) [CEL+CS+40%
Cipro@SEC] FAST. 40S) [CEL+CS+40% Cipro@SEC] SLOW. 50) [CEL+CS+50%
Cipro@SEC]. 60) [CEL+CS+60% Cipro@SEC]. A) 200x. B) 400x. C) 1000x. D) 3000x.

40F.A

40F.B

40F.C

40F.D
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Figure 3.29 (cont.): SEM images: 0) [CEL+CS]. 50SEC) [CEL+CS+50% SEC]. 20)
[CEL+CS+20% Cipro@SEC]. 30) [CEL+CS+30% Cipro@SEC]. 40F) [CEL+CS+40%
Cipro@SEC] FAST. 40S) [CEL+CS+40% Cipro@SEC] SLOW. 50) [CEL+CS+50%
Cipro@SEC]. 60) [CEL+CS+60% Cipro@SEC]. A) 200x. B) 400x. C) 1000x. D) 3000x.

40S.A

40S.B

40S.C

40S.D
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Figure 3.29 (cont.): SEM images: 0) [CEL+CS]. 50SEC) [CEL+CS+50% SEC]. 20)
[CEL+CS+20% Cipro@SEC]. 30) [CEL+CS+30% Cipro@SEC]. 40F) [CEL+CS+40%
Cipro@SEC] FAST. 40S) [CEL+CS+40% Cipro@SEC] SLOW. 50) [CEL+CS+50%
Cipro@SEC]. 60) [CEL+CS+60% Cipro@SEC]. A) 200x. B) 400x. C) 1000x. D) 3000x.

50.A

50.B

50.C

50.D
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Figure 3.29 (cont.): SEM images: 0) [CEL+CS]. 50SEC) [CEL+CS+50% SEC]. 20)
[CEL+CS+20% Cipro@SEC]. 30) [CEL+CS+30% Cipro@SEC]. 40F) [CEL+CS+40%
Cipro@SEC] FAST. 40S) [CEL+CS+40% Cipro@SEC] SLOW. 50) [CEL+CS+50%
Cipro@SEC]. 60) [CEL+CS+60% Cipro@SEC]. A) 200x. B) 400x. C) 1000x. D) 3000x.

60.A

60.B

60.C

60.D.1

60.D.2
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3.4. Conclusions
In summary, visual inspection of the [CEL+CS+Cipro@SEC] composites showed that
they were homogeneous in appearance, demonstrating that the Cipro@SEC was successfully
dispersed throughout the composite by the 3 minutes of mixing that were employed. As expected,
the color of the composite darkened slightly with higher and higher percentages of Cipro@SEC.
While the FTIR analysis unfortunately was not able to see the ciprofloxacin HCl that was
sequestered inside the inner cavity of the SEC, it was able to verify that washing the composites
with 2-propanol is an effective way to remove all traces of [BMIM+Cl-] ionic liquid from the
composite. FTIR analysis was also able to verify that drying the composites under vacuum under
the pressure of a lead brick for several hours is an effective method for the removal of 2-propanol
for the production of dry [CEL+CS+Cipro@SEC] composites. Furthermore, FTIR analysis also
demonstrated that the functional groups of the [CEL+CS] composite were not disrupted by the
addition of either SEC or Cipro@SEC. Inspection of the XRD spectra demonstrated the presence
of ciprofloxacin HCl, ciprofloxacin, and an anhydrous form of ciprofloxacin. The likeliest source
of the ciprofloxacin and the anhydrous ciprofloxacin is the spikes and sheets of ciprofloxacin HCl
that were observed via SEM analysis on the exterior surface of the SEC as discussed in Chapter 2.
The presence of ciprofloxacin HCl and ciprofloxacin were confirmed by inspection of the
fluorescence spectra, as well as a third component. A literature search allowed this third
component to be identified as ciprofloxacin at a pH of ~4. Analysis of the dried composites with
the SEM images allowed the smooth surface of the [CEL+CS] composite to be seen, although the
method of casting that was used does not allow for a perfectly smooth surface. It was also proven
that the addition of SEC does not significantly alter the appearance of the [CEL+CS+SEC]
composite when compared to the blank [CEL+CS] composite. Finally, as expected, the relative
abundance of the Cipro@SEC visible in the [CEL+CS+Cipro@SEC] composites increased as the
percentage of Cipro@SEC added was increased.
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Overall, it was successfully demonstrated that the majority of the ciprofloxacin HCl was
protected by the SEC into which it had been encapsulated, remaining in the same form as
demonstrated by fluorescence measurements. The ciprofloxacin HCl that had crystallized on the
outside of the SEC was not protected and led to the appearance of the ciprofloxacin bands that
were observed. This study was successful in demonstrating the feasibility of incorporating
ciprofloxacin HCl into [CEL+CS] composites in the form of Cipro@SEC, as well as revealing
that [CEL+CS] biopolymer composites can be successfully gelified and washed with a solvent
other than water.
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Chapter 4. CONCLUSION

4.1. Summary of Results
The produced Cipro@SEC were characterized visually, with confocal fluorescence
microscopy, analysis of SEM images, fluorescence spectra, XRD spectra, and FTIR spectra. The
Cipro@SEC produced in this study is a fine light brown powder. SEM analysis revealed that the
exterior of the SEC was coated with spikes and sheets of crystallized ciprofloxacin HCl. Confocal
fluorescence microscopy confirmed that the interior cavity of the SEC were completely filled
with ciprofloxacin HCl. This represents the first time ciprofloxacin HCl has been successfully
encapsulated inside sporopollenin exine capsules, demonstrating the suitability of the procedure
described here for that purpose.
The produced [CEL+CS+Cipro@SEC] composites were characterized visually and by
analysis of SEM images, fluorescence spectra, XRD spectra, and FTIR spectra. FTIR analysis
demonstrated that the functional groups of the [CEL+CS] composite were not altered by the
addition of either SEC or Cipro@SEC, and that both the [BMIM+Cl-] ionic liquid and the 2propanol were successively removed from the final composite by the synthetic procedure used
here. The dried [CEL+CS+Cipro@SEC] composites were found to contain ciprofloxacin HCl,
ciprofloxacin, and an anhydrous form of ciprofloxacin. SEM analysis demonstrated that the
[CEL+CS] composite was not disrupted or damaged by the addition of SEC or Cipro@SEC. As
expected, with progressively higher concentrations of Cipro@SEC the relative abundance of
Cipro@SEC also visibly increased.
Overall, it was successfully demonstrated that the ciprofloxacin HCl was protected by
being encapsulated into SEC before being incorporated into [CEL+CS] to form
[CEL+CS+Cipro@SEC] composites. However, the ciprofloxacin HCl that had crystallized on the
outside of the SEC was unprotected, leading to the appearance of the ciprofloxacin bands that
were observed. This study was successful in demonstrating the feasibility of incorporating
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ciprofloxacin HCl into [CEL+CS] composites in the form of Cipro@SEC, as well as
demonstrating that [CEL+CS] composites can be gelified and washed with 2-propanol instead of
water.
4.2. Future Research
Based on the results from Chapter 2, a next phase of research could be to investigate a
solvent that would allow for the removal of the exterior ciprofloxacin HCl from the Cipro@SEC,
while leaving the ciprofloxacin HCL in the interior undisturbed. This would likely require the use
of a solvent in which ciprofloxacin HCl is only weakly soluble. The solvent used in this work that
may prove to be suitable for this would 2-propanol. It may even be possible to “tune” the
solubility of the washing solvent by using a mixture of two alcohols, such as [1-octanol+2propanol], as it was found that the antibiotic was weakly soluble in 2-propanol but insoluble in
the 1-octanol that was used in the fluorescent confocal microscopy.
Based on the results that were discussed earlier regarding Chapter 3, composites made
from cellulose and chitosan mixtures that are gelified with a solvent other than water is a
promising avenue for research, providing the ability to incorporate encapsulated water-soluble
compounds of interest into a medically relevant biopolymer composite. Optimization of the
gelification solvent must first be investigated. Future research could also emphasize isolating the
synthesis of these composites from water, due to the swelling challenges that were encountered
when a composite was inadvertently allowed to gelify with both water and 2-propanol.
The Mylar plastic backing that was used to support the composite within the Teflon mold
is not ideal, given how the composite was observed to shrink non-uniformly due to the adherence
of the bottom surface of the composite to the Mylar plastic, while the top surface was free to
contract. This led to the development of a trapezoidal shape when the composite was viewed from
the side. A possible alternative would be to use a thin sheet of Teflon in place of the Mylar.
In order to further elucidate the suitability of these composites for medical applications, it
will be necessary to measure the drug delivery properties, the antibacterial activity, and the
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behavior and effect of the composites when applied to actual wounds. When these tests have been
completed, the composites can then be used as bandages for the treatment of infected wounds in
unfriendly environments.

